Skip to main content
Smart Investors Daily
BL

NASDAQ · BLUW

Blue Water Acquisition Corp III

Financial Services · Shell Companies

$10.36

Up+$0.01 (+0.10%)

Updated Aug 16, 2026, 1:22 PM

SID Score

4.5/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
333.42M
P/E ratio
98.13
Dividend yield
0.00%
52-week range
$9.93 – $10.41
Volume
8.56K
Avg. volume
106.95K

Price performance

BLUW price history

1M range · 0 trading sessions · Daily adjusted prices

BLUW does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest BLUW news

The latest Smart Investors Daily articles mentioning BLUW.

BLUW research

Overview

Company profile and research snapshot.

Company profile

Blue Water Acquisition Corp III is a blank check company.

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Average target
Implied upside
Analysts
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Dec 5, 2025

Blue Water Acquisition Corp. IV, Sponsored by Serial Entrepreneur Joseph Hernandez, Files $125Million IPO Registration Statement with the U.S. Securities and Exchange Commission

Blue Water Acquisition Corp. IV (the "Company"), a newly formed special purpose acquisition company, announced today that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) in connection with its proposed $125 million initial public offering.

GlobeNewswire Inc. · Aug 27, 2021

Blue Water Acquisition Corp. Announces Stockholder Approval of Business Combination with Clarus Therapeutics, Inc.

GREENWICH, Conn., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (Nasdaq: BLUW), a special purpose acquisition company (“Blue Water”), today announced that its stockholders have voted to approve the proposed business combination (the “Business Combination”) with Clarus Therapeutics, Inc., a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women (“Clarus”) at its special meeting of stockholders (the “Special Meeting”) held today, August 27, 2021.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.